Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom

Sponsor
AbbVie
Study ID
NCT07690215
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the effectiveness of atogepant for the preventive treatment of migraine in adult patients in the UK. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 200 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in the UK. Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 48. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Key Dates

First listed
Jul 8, 2026
Start date
Sep 1, 2026
Status verified
Jul 2026
Primary completion
Mar 31, 2028
Completion
Mar 31, 2028

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Atogepant
    Participants will receive atogepant as prescribed by their physician according to the local label.

Primary Outcome Measure

Percentage of Participants Achieving a Rating of "Much Better" or "Very Much Better" Following Atogepant Initiation As Assessed by Patient's Global Impression of Change (PGI-C) [ Time Frame: Up to approximately 12 Weeks ]

Central Contacts

Find similar trials

Related Studies